RA Capital Management
Venture Capital
Active
Boston, United States
411
86M
296
17.87
71
0.28
123
- Stages of investment
- Areas of investment
Summary
RA Capital Management appeared to be the VC, which was created in 2001. The leading representative office of defined VC is situated in the Boston. The venture was found in North America in United States.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the RA Capital Management, startups are often financed by OrbiMed, F-Prime Capital, Flybridge Capital Partners. The meaningful sponsors for the fund in investment in the same round are Wellington Management, Longitude Capital, Deerfield. In the next rounds fund is usually obtained by OrbiMed, Cormorant Asset Management, Polaris Partners.
Opposing the other organizations, this RA Capital Management works on 23 percentage points more the average amount of lead investments. The fund is generally included in 7-12 deals every year. The real fund results show that this VC is 4 percentage points more often commits exit comparing to other companies. The average startup value when the investment from RA Capital Management is more than 1 billion dollars. The increased amount of exits for fund were in 2015. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 50 - 100 millions dollars.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline AveXis, Moderna Therapeutics, Intarcia Therapeutics Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Health Diagnostics.
This organization was formed by Richard Aldrich. We also calculated 4 valuable employees in our database.
Investor highlights
- Industry focus
- Stage focus
- Check size
- 600K — 75M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 461000000
- Fund raised date
- 2020-10-22
Analytics
- Total investments
- 411
- Lead investments
- 71
- Exits
- 123
- Rounds per year
- 17.87
- Follow on index
- 0.28
- Investments by industry
- Biotechnology (352)
- Health Care (225)
- Therapeutics (150)
- Pharmaceutical (114)
- Medical (108) Show 54 more
- Investments by region
-
- United States (333)
- United Kingdom (14)
- China (7)
- Canada (13)
- Denmark (7) Show 10 more
- Peak activity year
- 2021
- Number of Unicorns
- 8
- Number of Decacorns
- 8
- Number of Minotaurs
- 16
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 89M
- Group Appearance index
- 0.95
- Avg. company exit year
- 7
- Avg. multiplicator
- 2.81
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Bright Peak Therapeutics | 11 Jun 2024 | Biotechnology, Therapeutics | Late Stage Venture | 90M | Switzerland, Basel-City, Basel |
TORL BioTherapeutics | 10 Apr 2024 | Biotechnology, Biopharma, Clinical Trials | Early Stage Venture | 158M | United States, California, Los Angeles |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.